Patents Examined by Gary Benzion
  • Patent number: 10329601
    Abstract: This invention relates to compositions, methods and kits for detecting the presence or absence of a bacterial species in a biological sample using isothermal nucleic acid amplification.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: June 25, 2019
    Assignee: Ionian Technologies, Inc.
    Inventors: Daiwei Shen, Richard Roth, Honghua Zhang
  • Patent number: 10329630
    Abstract: Compositions and methods for detecting presence of an emerging influenza virus in a sample, such as a biological sample obtained from a subject or an environmental sample, are disclosed. In some embodiments, the compositions and methods can be used to quickly identify particular subtypes of influenza virus (such as a pandemic and/or emerging influenza virus subtype). Probes and primers are provided herein that permit the rapid detection and/or discrimination of pandemic influenza virus subtype nucleic acids in a sample. Devices (such as arrays) and kits for detection and/or discrimination of influenza virus subtype nucleic acids are also provided.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: June 25, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bo Shu, Stephen Lindstrom
  • Patent number: 10323267
    Abstract: A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: June 18, 2019
    Assignee: Becton Dickinson and Company
    Inventors: Feng Yang, Sha-Sha Wang, Laurence Michael Vaughan, Michael Porter, Elaine Rose
  • Patent number: 10307762
    Abstract: Provided is a thermal cycler including a housing, the housing with a thermal block having sample wells, each for receiving a test sample in a sample vessel, an electric heater for heating the thermal block, a power supply and an electronic control for controlling the electric heater, and a temperature analysis and/or verification unit for analyzing and/or verifying a thermal performance of the thermal block. Also provided is a method for analyzing or verifying a thermal performance of a thermal cycler and for calibrating the thermal cycler. The thermal cycler has a temperature analysis and/or verification unit integrated into the housing and connected to the power supply and electronic control by an internal interface, whereas the method is characterized by the following steps: providing the thermal cycler with an integrated temperature analysis and/or verification unit and using the integrated temperature analysis and/or verification unit for self-calibration of the thermal cycler.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: June 4, 2019
    Assignee: Hahn Lifescience GmbH
    Inventor: James Courtney
  • Patent number: 10266882
    Abstract: Disclosed are a human rare blood type detection method, a kit, a rapid screening method and applications thereof. By using multiple pairs of PCR specific primers directing to the SNP loci of multiple rare blood types, the SNP loci of multiple rare blood types are simultaneously detected in the same PCR reaction system; and the multiplex PCR detection method and a Pool detection method are combined to rapidly screen the human rare blood types.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: April 23, 2019
    Assignee: SHANGHAI BLOOD CENTRE
    Inventors: Luyi Ye, Ziyan Zhu, Zhonghui Guo, Yunlei He, Huanhuan Gao, Pan Wang, Li Xie, Aoxue Zhu, Wei Zhang, Wenjie Gao, Qixiu Yang
  • Patent number: 10266877
    Abstract: Based on the structural features of KIR full genomic sequences, the distribution of single nucleotide polymorphisms in their coding regions and the length of flanking intronic sequence of each exon, a method for high-throughput simultaneous sequence-based typing of all the 14 functional killer cell immunoglobulin-like receptor (KIR) genes is disclosed including: developing a scientific and reasonable polymerase chain reaction (PCR) amplification strategy; simultaneously amplifying the complete coding sequence of each functional KIR gene using 3˜5 pairs of KIR gene-specific PCR primers that have similar annealing temperature; and determining the nucleotide sequences of the exons carried by each PCR amplicon in both directions using the forward and reverse sequencing primers, respectively, as shown in FIG. 1.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 23, 2019
    Assignee: SHENZHEN BLOOD CENTER
    Inventors: Zhihui Deng, Jianxin Zhen, Guobin Zhang
  • Patent number: 10266889
    Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: April 23, 2019
    Assignees: ROCHE FINANCE LTD, INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, John Robert Havens, Mirna Jarosz, Zachary Zwirko, Doron Lipson, Frank Soo Juhn
  • Patent number: 10253370
    Abstract: A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 9, 2019
    Assignee: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher Albitar
  • Patent number: 10221457
    Abstract: A method for measuring blood levels of ? cell DNA that is released upon ? cell death by using a quantitative probe technology to detect amplified methylated and demethylated forms of the insulin gene DNA, representing normal tissue and ? cell specific origin, respectively. Using probes permits the sensitive and specific identification of demethylated insulin DNA patterns that are present only in ? cells. The method offers a bioassay for detecting ? cell loss in diabetes, useful for screening of prediabetes, monitoring of disease progression, and selection and monitoring of therapies. The technique finds potential use in both Type I and Type II diabetes, as well as gestational diabetes.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: March 5, 2019
    Assignee: NYU Winthrop Hospital
    Inventor: Eitan Moshe Akirav
  • Patent number: 10214783
    Abstract: A method is provided for determining the zygosity of an Rf4 gene in a corn plant. A method may include performing a first PCR assay, a second PCR assay, quantifying probes used in the first and second PCR assays, and comparing the quantified probes to determine zygosity.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: February 26, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Ruihua Ren, Peizhong Zheng, Siva Prasad Kumpatla
  • Patent number: 10214780
    Abstract: The present invention is concerned with a method of rapid identification of a mammalian species origin or mammalian species origins of a sample.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 26, 2019
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventors: Shuk Han Cheng, Chun Chi Lin
  • Patent number: 10113178
    Abstract: The invention provides recombinant DNA molecules that are unique to the maize MON 87419 event and transgenic maize plants, plant parts, seeds, cells, and agricultural products containing the MON 87419 event as well as methods of using and detecting the maize MON 87419 event. Transgenic maize plants containing the MON 87419 event exhibit tolerance to dicamba and glufosinate herbicides.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: October 30, 2018
    Assignee: Monsanto Technology LLC
    Inventors: Wen C. Burns, Michael E. Goley, Jintai Huang, Melinda C. McCann, Aihua Shao, Oscar C. Sparks, Martin A. Stoecker, Liping Wei
  • Patent number: 9580759
    Abstract: The current disclosure generally relates to the field of saxitoxins and the identification of microorganisms capable of producing them. In particular, the saxitoxin A (sxtA) gene comprising catalytic domain sequences saxitoxin A1 (sxtA1) and saxitoxin A4 (sxtA4) is identified in a number of dinoflagellate species. The disclosure relates to methods of detection of saxitoxin-producing dinoflagellates by amplification and detection of the sxtA gene (in particular by PCR) and kits and primers for use in the method are also disclosed. Saxitoxin-producing dinoflagellate genera detected by the method include Alexandrium, Pyrodinium or Gymnodinium.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: February 28, 2017
    Assignees: UNIVERSITETET I OSLO, NEWSOUTH INNOVATIONS PTY LIMITED
    Inventors: Brett A. Neilan, Shauna Ann Murray, Anke Corinna Stüken, Kjetill S. Jakobsen, Russel J. S. Orr, Ralf Kellmann
  • Patent number: 9499847
    Abstract: A primer for the amplification of a DNA template comprising a protelomerase target sequence, particularly for production of closed linear DNA, which primer is capable of specifically binding to a palindromic sequence within a protelomerase target sequence and priming amplification in both directions.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: November 22, 2016
    Assignee: Touchlight IP Limited
    Inventors: Neil Porter, Lisa Caproni, Karen Oliver, Kinga Karbowniczek, Angus Knight
  • Patent number: 9499860
    Abstract: A primer and method for amplification of a target nucleic acid, the primer adapted to conform into a conformation that dissociates from a complementary strand of DNA duplex. The conformation may have a free energy with more favorable thermodynamics than a corresponding DNA duplex, such as a B-DNA duplex. The dissociation may occur during an extension step of an amplification method, such as polymerase chain reaction. The method can proceed isothermally, and the primers may include intrinsic fluorescence.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: November 22, 2016
    Assignee: The Ohio State University
    Inventor: Besik Kankia
  • Patent number: 9487818
    Abstract: The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity in vitro. The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: November 8, 2016
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Somasundaram Kumaravel, Arivazhagan Arimappamagan, Kandavel Thennarasu, Alangar Sathyaranjandas Hegde, Ashwathnarayana Chandramouli, Santosh Vani, Paturu Kondaiah, Satyanarayana Rao Manchanahalli Rangaswamy
  • Patent number: 9487835
    Abstract: Methods and compositions for detecting, identifying, and quantifying Brassica A genomic DNA are described. The methods are specific to the Brassica A genome and do not cross-react with other Brassica species, crops or weedy relatives that could contribute to contamination of a canola field.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 8, 2016
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Matthew Curtis Harmon, Nancy L Henderson, Cathy Xiaoyan Zhong
  • Patent number: 9458498
    Abstract: The present invention pertains to: a method for modifying a nucleic acid contained in a sample, the method including a step for bringing the sample into contact with a nucleic acid-modifying agent in the presence of an acidic polysaccharide and/or a nucleotide; and a method for selectively detecting a nucleic acid derived from living cells contained in the sample, the method including the following steps: (a) a step for modifying a nucleic acid contained in a sample according to the method for modifying a nucleic acid contained in a sample, which includes a step for bringing the sample into contact with a nucleic acid-modifying agent in the presence of an acidic polysaccharide and/or a nucleotide; and (b) a step for selectively detecting an unmodified nucleic acid from the sample after step (a). The present invention further pertains to a kit and composition for use in these methods.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: October 4, 2016
    Assignee: TAKARA BIO INC.
    Inventors: Junko Yamamoto, Keiko Kubo, Takashi Uemori, Hiroyuki Mukai, Kiyozo Asada
  • Patent number: 9340826
    Abstract: Provided is a method of preparing nucleic acid molecules comprising: (a) a step of providing nucleic acid fragments constituting at least a portion of the complete sequence of a target nucleic acid; (b) tagging the nucleic acid fragments with barcode sequences; (c) identifying the sequence of the nucleic acid fragments tagged by the barcode sequences; and (d) recovering desired nucleic acid fragments among the sequence-identified nucleic acid fragments using the barcode sequences.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: May 17, 2016
    Assignee: CELEMICS, INC.
    Inventors: Duhee Bang, Hwangbeom Kim, Hyojun Han
  • Patent number: 9328391
    Abstract: The determination of the nucleotide sequence of HIV-1 DNA; identification, isolation and expression of HIV-1 DNA sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HIV-1.
    Type: Grant
    Filed: January 23, 1985
    Date of Patent: May 3, 2016
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Nancy T. Chang, Robert C. Gallo, Flossie Wong-Staal